Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Céleste Lebbé"'
Autor:
Wanxing Chai-Ho, Jenny H. Lee, Ignacio Melero, Andrew Haydon, Nikhil I. Khushalani, Jose Lutzky, Andrew F. Hill, Gregory A. Daniels, Muhammad Alamgeer, Ragini R. Kudchadkar, Dimitrios Colevas, Ann Silk, Piyush Sheladia, Daniel Brungs, Shui He, Praveen K. Bommareddy, Frances A. Collichio, Samantha Bowyer, Céleste Lebbé, Michael R. Migden, Danny Rischin, Jean-jaques Grob, Matthew G. Fury, Claudia Andreu-Vieyra
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundThe prognosis for advanced and metastatic cutaneous squamous cell carcinoma (CSCC) remains poor for many patients with the disease despite approval of the anti-PD1 antibodies cemiplimab and pembrolizumab.1 2 RP1 is an oncolytic virus (HSV-1
Autor:
Sandra P. D'Angelo, Gerald P. Linette, Shailender Bhatia, Michele Milella, Karl D. Lewis, Isaac Brownell, Patrick Terheyden, G. Guezel, Paul Nghiem, A.S. Brohl, Kent C. Shih, Janice M. Mehnert, Céleste Lebbé, Omid Hamid, Huiling Xiong
Publikováno v:
ESMO Open
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer that has a poor prognosis in patients with advanced disease. Avelumab [anti-programmed death-ligand 1 (PD-L1)] became the first approved treatment for patients with metastatic M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd963611621e7ce24520f15651c37b28
http://hdl.handle.net/11562/1063645
http://hdl.handle.net/11562/1063645
Autor:
Philip Friedlander, Claudia Pföhler, Michael Max Sachse, Max Schlaak, Carola Berking, Lavinia Spain, Alexander M. Menzies, Friedegund Meier, Rafaela Kramer, Kinan Hayani, Céleste Lebbé, Katharina C. Kähler, Lisa Zimmer, Milena Dudda, Anne Zaremba, Alvaro Moreira, Jessica C. Hassel, Georgina V. Long, Barouyr Baroudjian, Lydia Reinhardt, Alison Weppler, Adriana Hepner, Matteo S. Carlino, Carmen Loquai, Paul J Bröckelmann, Anja Gesierich, Tomohiro Enokida, Douglas B. Johnson, Lucie Heinzerling, Thomas Eigentler, Makoto Tahara, Martin Salzmann, Selma Ugurel
Introduction With the increasing use of checkpoint inhibitors, rare immune-related adverse events (irAE) are being identified. Haematological irAE (hem-irAE) are difficult to treat and have shown high mortality rates. In order to improve side-effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbea5c242e2582a869d1911e0b68e0cd
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85102118984
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85102118984
Autor:
Céleste Lebbé, Katharina C. Kähler, Egle Ramelyte, Elisabeth Livingstone, Lucie Heinzerling, Axel Hauschild, Phil F. Cheng, Frédéric Toussaint, Camille L. Gerard, Paolo A. Ascierto, Joanna Mangana, Clara Allayous, Sarah Schäfer, Reinhard Dummer, Anne Zaremba, Jessica C. Hassel, Florentia Dimitriou, Lucia Festino, Olivier Michielin
Publikováno v:
European journal of cancer (Oxford, England : 1990). 149
Background Anti-PD1–based immunotherapy is currently used in most patients with advanced melanoma. Despite the remarkable data regarding overall survival, the optimal treatment duration is still unknown. Methods We evaluated the outcome of 125 pati
Autor:
Céleste Lebbé, Armin Schueler, Richard Isaacs, Giorgio Massimini, Willem Kruit, Brigitte Dreno, Virginia Ferraresi, Caroline Robert, Luc Thomas, Enrique Espinosa, Carmen Loquai, Paul Vasey, Joseph Kerger, Bernard Guillot, Jean-Jacques Grob, Robert M. Conry, Caroline Dutriaux, Claus Garbe, Filippo de Braud, Thierry Lesimple
Publikováno v:
Cancers
Cancers, MDPI, 2020, 12 (7), pp.1727. ⟨10.3390/cancers12071727⟩
Cancers, 12(7):1727. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers (Basel), 12 (7
Cancers, 2020, 12 (7), pp.1727. ⟨10.3390/cancers12071727⟩
Volume 12
Issue 7
Cancers, Vol 12, Iss 1727, p 1727 (2020)
Cancers, MDPI, 2020, 12 (7), pp.1727. ⟨10.3390/cancers12071727⟩
Cancers, 12(7):1727. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers (Basel), 12 (7
Cancers, 2020, 12 (7), pp.1727. ⟨10.3390/cancers12071727⟩
Volume 12
Issue 7
Cancers, Vol 12, Iss 1727, p 1727 (2020)
This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 NRAS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6beadf3f227784dd0a386688cda16602
https://hal.umontpellier.fr/hal-03256625
https://hal.umontpellier.fr/hal-03256625
Autor:
Vanna Chiarion-Sileni, Céleste Lebbé, Catriona M. McNeil, Joanna Pikiel, Jean-Jacques Grob, Luc Thomas, Lars Bastholt, Andrzej Mackiewicz, Michele Maio, Omid Hamid, Virginia Ferraresi, Marta Nyakas, Caroline Robert, Michelle Del Vecchio, Burcin Simsek, Michael Smylie, Laurent Mortier, Dirk Schadendorf, Carmen Loquai, Inge Marie Svane, Ana Arance, Gabriella Liszkay, Fareeda Hosein, Piotr Rutkowski, Paolo A. Ascierto, Florent Grange, Christoph Hoeller, Brigitte Dréno, Ralf Gutzmer, Claus Garbe
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 2020, 8 (1), pp.e000391. ⟨10.1136/jitc-2019-000391⟩
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for ImmunoTherapy of Cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for immunotherapy of cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for Immunotherapy of Cancer, 2020, 8 (1), pp.e000391. ⟨10.1136/jitc-2019-000391⟩
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for ImmunoTherapy of Cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for immunotherapy of cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundWe have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::510133352a63b0beb0ad853bb98c25db
https://www.ncbi.nlm.nih.gov/pubmed/32503946
https://www.ncbi.nlm.nih.gov/pubmed/32503946
Autor:
Céleste Lebbé, Martine Bagot, Nicolas Meyer, Pierre Vabres, Jean-Jacques Grob, Caroline Dutriaux, N. Poulalhon, Christine Mateus, Nicole Basset-Seguin, Florian Herms, Laurent Mortier, Jérôme Lambert, Géraldine Jeudy, Bernard Guillot, Luc Haudebourg, Sandrine Monestier, Sophie Dalac, Sorilla Prey, Caroline Robert
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37(34)
PURPOSE Vismodegib is a hedgehog pathway inhibitor indicated for the treatment of locally advanced basal cell carcinoma (laBCC), with an objective response rate of 65%, including a 32% complete response (CR). However, adverse effects often lead to dr
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Philippe Bertheau, Cécile Pagès, Céleste Lebbé, Nelson Lourenco, Nadim Mourad, Julie Delyon, Matthieu Allez, Clara Allayous, A. Ballon, Barouyr Baroudjian, Pirayeh Eftekhari
Publikováno v:
Melanoma research. 29(5)
Gastrointestinal toxicities of MEK inhibitors in melanoma patients are frequent. In clinical trials, the most common digestive adverse events were nausea, vomiting, and diarrhoea. However, severe toxicities such as colitis and gastrointestinal perfor
Autor:
Pierre-Alexandre Squara, Jean-François Gautier, Marie-Léa Gauci, Matthieu Resche-Rigon, Clara Allayous, Céleste Lebbé, Julie Delyon, Barouyr Baroudjian, Philippe Boudou, Samia Mourah
Publikováno v:
Melanoma research. 29(3)
Immunotherapy greatly improves clinical outcomes in treated patients with cancer. However, the long-lasting immune response and long duration of therapy could induce long-term adverse effects owing to the chronic inflammation induced. Type 2 diabetes